Currently, cGAS‐STING inhibitors have been shown to be effective in alleviating myocardial infarction (MI) [53] and doxorubicin induced cardiotoxicity.[54] However, this strategy raises the risk of silencing immune responses in the presence of an infection. The gene discussed is STING1; the disease is infection.